The stock has a 36-month beta value of 1.08. Opinions on the stock are mixed, with 2 analysts rating it as a “buy,” 1 as “overweight,” 0 as “hold,” and 0 as “sell.”
The public float for DVAX is 114.40M, and at present, short sellers hold a 13.26% of that float. On July 03, 2025, the average trading volume of DVAX was 2.33M shares.
DVAX) stock’s latest price update
The stock of Dynavax Technologies Corp (NASDAQ: DVAX) has increased by 0.99% when compared to last closing price of $10.06.Despite this, the company has seen a gain of 3.04% in its stock price over the last five trading days. reuters.com reported 2025-06-11 that Biopharmaceutical company Dynavax Technologies on Wednesday defeated investment firm Deep Track Capital’s effort to unseat directors when investors re-elected all four candidates, the company said.
DVAX’s Market Performance
Dynavax Technologies Corp (DVAX) has seen a 3.04% rise in stock performance for the week, with a 3.25% gain in the past month and a -20.06% plunge in the past quarter. The volatility ratio for the week is 3.32%, and the volatility levels for the past 30 days are at 3.46% for DVAX. The simple moving average for the last 20 days is 0.78% for DVAX’s stock, with a simple moving average of -14.44% for the last 200 days.
Analysts’ Opinion of DVAX
Many brokerage firms have already submitted their reports for DVAX stocks, with Goldman repeating the rating for DVAX by listing it as a “Sell.” The predicted price for DVAX in the upcoming period, according to Goldman is $12 based on the research report published on February 11, 2025 of the current year 2025.
Goldman, on the other hand, stated in their research note that they expect to see DVAX reach a price target of $20. The rating they have provided for DVAX stocks is “Neutral” according to the report published on February 01st, 2024.
JMP Securities gave a rating of “Mkt Outperform” to DVAX, setting the target price at $22 in the report published on September 27th of the previous year.
DVAX Trading at -0.34% from the 50-Day Moving Average
After a stumble in the market that brought DVAX to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -30.55% of loss for the given period.
Insider Trading
Reports are indicating that there were more than several insider trading activities at DVAX starting from Novack David F, who sale 10,000 shares at the price of $14.00 back on Mar 24 ’25. After this action, Novack David F now owns 8,078 shares of Dynavax Technologies Corp, valued at $140,000 using the latest closing price.
Stock Fundamentals for DVAX
Current profitability levels for the company are sitting at:
- -0.03 for the present operating margin
- 0.82 for the gross margin
The net margin for Dynavax Technologies Corp stands at -0.2. The total capital return value is set at -0.01. Equity return is now at value -10.45, with -6.22 for asset returns.
Based on Dynavax Technologies Corp (DVAX), the company’s capital structure generated 0.35 points at debt to capital in total, while cash flow to debt ratio is standing at 0.22. The debt to equity ratio resting at 0.54. The interest coverage ratio of the stock is -1.54.
Currently, EBITDA for the company is 45.7 million with net debt to EBITDA at -4.31. When we switch over and look at the enterprise to sales, we see a ratio of 4.94. The receivables turnover for the company is 5.21for trailing twelve months and the total asset turnover is 0.31. The liquidity ratio also appears to be rather interesting for investors as it stands at 11.93.
Conclusion
To sum up, Dynavax Technologies Corp (DVAX) has seen a mixed performance recently. Analysts have differing views on the stock, with some seeing it as a “buy” and others as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
